Results 31 to 40 of about 776,387 (309)

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Comprehensive genomic profiling of combined small cell lung cancer

, 2021
Background: Combined small cell lung cancer (CSCLC) is an uncommon and heterogeneous subtype of small cell lung cancer (SCLC). However, there is limited data concerning the different molecular changes and clinical features in CSCLC compared to pure SCLC.
Jiang, Gening, Zhang, Peng, Goto, Taichiro, Wu, Chunyan, Cardona, Andrés F., Chen, Qiankun, Zhang, Liping, Zhu, Yuming, Hou, Likun, Yu, Huansha, Zhang, Jing, Santarpia, Mariacarmela, Malhotra, Jyoti, Luo, Jie, Troncone, Giancarlo, Sun, Liangdong, Okuda, Katsuhiro, Li, Junqiang, Fan, Pengyu, Wu, Chunxiao, Zamarchi, Rita, Xu, Jianfang, Zhang, Zhonghong, Ge, Tao   +23 more
core   +1 more source

Transferrin receptor 1‐mediated iron uptake supports thermogenic activation in human cervical‐derived adipocytes

FEBS Letters, EarlyView.
In this study, we found that human cervical‐derived adipocytes maintain intracellular iron level by regulating the expression of iron transport‐related proteins during adrenergic stimulation. Melanotransferrin is predicted to interact with transferrin receptor 1 based on in silico analysis.
Rahaf Alrifai, Mizuki Seo, Gyath Karadsheh, Fachrur Rizal Mahendra, Máté Á Demény, Ferenc Győry, János András Mótyán, László Fésüs, Endre Kristóf, Rini Arianti   +9 more
wiley   +1 more source

Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer

Chinese Journal of Lung Cancer, 2021
Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD-1) antibody, programmed cell death ligand 1 (PD-L1) antibody, and cytotoxic T ...
Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy, Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer   +1 more
doaj   +1 more source

Non-small-cell lung cancer: how to manage RET-positive disease

Drugs in Context, 2022
Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC). RET rearrangements are typically observed in about 1–2% of NSCLC, resulting in constitutive activation of downstream signalling ...
Elisa Andrini, Mirta Mosca, Linda Galvani, Francesca Sperandi, Biagio Ricciuti, Giulio Metro, Giuseppe Lamberti   +6 more
doaj   +1 more source

Blueprint Of Services For Lung Cancer [PDF]

, 1995
Primary lung cancer is the commonest malignant disease in the developed world, and is the most prevalent form of cancer among men over 65 years. It continues to rise in those aged over 75 years. Mortality from lung cancer is increasing in women.
Doyle, Yvonne G.
core  

Three phosphatase families form a community: The phosphohydrolases that act upon inositol pyrophosphates

FEBS Letters, EarlyView.
Inositol pyrophosphates are energy‐rich signaling molecules that perform critical functions in cells. Three different families of phosphatases hydrolyze the β phosphate of the inositol pyrophosphate molecules: two have narrow specificities and one is promiscuous.
Ronda J. Rolfes
wiley   +1 more source

Non-small-cell lung cancer: how to manage EGFR-mutated disease

Drugs in Context, 2022
The treatment of non-small-cell lung cancer (NSCLC) harbouring EGFR mutations has witnessed some major breakthroughs in the last years. On the one hand, the recent advent of the third-generation tyrosine kinase inhibitor (TKI) osimertinib has reshaped ...
Federica Pecci, Luca Cantini, Giulio Metro, Biagio Ricciuti, Giuseppe Lamberti, Ammad Ahmad Farooqi, Rossana Berardi   +6 more
doaj   +1 more source

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group [PDF]

, 2005
Purpose: This phase III randomized trial compared two chemotherapy regimens, gemcitabine plus carboplatin and mitomycin, ifosfamide, and cisplatin, in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC).
Harper, P.G., Johnson, P.W.M., Harper, P. G., Qian, W., Rudd, R. M., Spiro, S.G., Gregory, W. M., Hatton, M., Eisen, T. G., James, L.E., Rankin, E. M., Johnson, P. W. M., Rankin, E.M., Spiro, S. G., Rudd, R.M., Lee, S. M., Littler, J. A. H., Lee, S.M., Littler, J.A.H., Eisen, T.G., Martin, W.M.C., Gregory, W.M., James, L. E., Gower, N. H., Martin, W. M. C., Gower, N.H.   +25 more
core   +1 more source

Engineered extracellular vesicles enriched with the miR‐214/199a cluster enhance the efficacy of chemotherapy in ovarian cancer

Molecular Oncology, EarlyView.
Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang, Ayesha Alvero, Yi Qin, Mingjin Wang, Alexandra Fox, Yanfeng Li, Michael Millman, Amy Kemper, Gil Mor, Xian Shuang Liu, Michael Chopp, Zheng Gang Zhang, Yi Zhang   +12 more
wiley   +1 more source